Elite Hospital, "Difficult" Turnaround: What Exactly Is Broken at Summa Health?

Summa Health System's Akron Campus just earned the Healthgrades 2026 America's 50 Best Hospitals Award for the third consecutive year, placing it in the top 1% of U.S. hospitals nationwide. At the same time, the hospital's new acting CEO Daryl Tol frames Summa as a turnaround project his firm acquired precisely because "they knew it would be difficult". Tol says Akron was intentionally selected because transforming healthcare in a lower-growth market would make the effort harder for the industry to ignore.

The paradox raises an urgent question for Akron residents: what exactly needs fixing at a hospital already delivering elite clinical outcomes?

Top 1% Clinical Performance, Three Years Running

The Healthgrades America's 50 Best Hospitals Award recognizes only the top 1% of U.S. hospitals based on clinical excellence, using Medicare data from 2022 to 2024. Summa Health Akron Campus has earned this distinction for three consecutive years—2024, 2025, and 2026.

Medicare patients at Summa experience a 27.4% lower risk of dying compared to non-award hospitals across 19 conditions. The system is ranked #1 in Ohio for Neurosciences, Cranial Neurosurgery, Critical Care, and Stroke Care, and is recognized as one of the 50 Top Cardiovascular Hospitals in the nation. Its bleeding complication rate for acute stroke treatment was 2.5% in 2025, significantly outperforming the national goal of 6.0%, and it reduced hemorrhagic stroke readmissions by 4.1% in 2025, achieving a 7.5% rate—the lowest in four years.

New Leadership Frames Summa as "Difficult" Turnaround

Daryl Tol serves as President and CEO of General Catalyst's Health Assurance Transformation Company (HATCo) and acting President and CEO of Summa Health. HATCo completed its acquisition on June 1, 2026, for $515 million—the first major hospital system acquired and operated by a venture capital firm, described as a watershed moment for venture capital in healthcare. The deal eliminated approximately $850 million in existing debt and transitioned Summa from nonprofit to for-profit operation.

Tol explicitly frames the acquisition as an opportunity to transform healthcare in the region, using Summa as a test lab for broader U.S. healthcare transformation rather than pursuing short-term financial gains.

"The system's demand for certainty stifles innovation, which requires uncertainty and curiosity instead," Tol says.

His priorities include deploying AI to mitigate workforce shortages, simplifying billing, and developing a single reinvented healthcare interface for managing care and payment. "Healthcare workers need better tools to eliminate wasteful work so they can spend more time doing the work of their heart and passion," he explains.

The Core Tension: Clinical Excellence Meets Operational "Difficulty"

If Summa's clinical outcomes place it in the top 1% nationally, what makes this a "difficult" turnaround?

The system reported a narrow operating loss of $8 million in fiscal year 2024 despite approximately $2 billion in total revenue, facing rising supply costs, reimbursement changes, and the $850 million debt burden carried from its nonprofit era. Summa leadership described its financial standing as sound with a positive outlook before the acquisition.

HATCo committed $550 million in long-term capital investment: $350 million for routine operations in the first five years and $200 million for strategic and transformative innovation in the first seven.

The "difficulty" Tol references appears to center on operational efficiency, billing complexity, workforce shortages, and market dynamics—not on the quality of patient care. "Training enough human providers will never overcome access gaps," Tol argues. "Wait times, lack of access to primary and specialty care, and insufficient nursing staff are systemic failures requiring new solutions".

For patients, "success" means maintaining elite clinical outcomes; for new ownership, it may be measured in operational efficiency, financial margins, and scalable innovation.

What the Paradox Means for Akron's Healthcare Future

Summa Health has served Northeast Ohio for over 130 years, formed in 1989 by the merger of Akron City Hospital (founded 1892) and St. Thomas Hospital (opened 1922). It serves more than 1 million patients yearly across a five-county region with 8,500+ employees and 1,049 licensed beds.

Not everyone welcomes the new ownership. The Summa Is Not For Sale coalition, composed of local residents and community advocates, opposed the conversion, citing risks to patient access, community benefit, and potential misuse of charitable assets. Studies indicate that quality of care can worsen and prices rise after venture capital and private equity hospital transactions, and regulators and patient advocates remain wary that pledges may be abandoned if they conflict with profit-making objectives.

The Ohio Attorney General imposed regulatory conditions on the sale, including an additional $30 million ($15 million cash and $15 million equity) to Summa's nonprofit foundation. Eight months after the acquisition, Summa executives rolled out AI phone calls to help patients prepare for surgery and navigate post-discharge care as part of the transformation plan.

General Catalyst views the acquisition as a long-term commitment intended to serve as a blueprint for the broader healthcare industry, aiming to test improvements without the risk aversion or cash shortfalls common among traditional providers.

Whose Definition of Success Will Prevail?

The central question for Akron residents: can an ownership group optimize for efficiency and financial returns while preserving the clinical excellence that earned Summa three consecutive top-1% national rankings?

The hospital is already succeeding by the measure that matters most to patients—delivering care that saves lives and reduces complications. Whether transformation strengthens or compromises that excellence will depend on whose priorities shape decisions: venture capital investors seeking a scalable blueprint, or the million-plus Northeast Ohio patients who rely on Summa for care.

For a community that has depended on Summa for over a century, the stakes are deeply personal—and the answer may determine the future of healthcare access and quality across the region.